|  |
| --- |
| **Supplementary Table 8S. Outcome and EBOV Genome Equivalents in Plasma and CSF from Experiment 2 Back Challenge** |
| Treatment | Animal ID | *In vivo* outcome(days after 2nd challenge) | qPCR at necropsy (GE/mL) |
| Plasma | CSF |
| EI: SAB-139/V6-V8 | 3 | D9 | 8.3E8 | 1.9E5 |
| 4 | D6 | 6.3E9 | 8.8E4 |
| 5 | D7 | 3.6E10 | 2.8E7 |
| 6 | S21 | <LOQ | <LOQ |
| 7 | D9 | NT | NT |
| 8 | D10 | 9.9E9 | 2.7E6 |
| DI: SAB-139/V6-V8 | 9 | Not challenged | NT | NT |
| 10 | S21 | <LOQ | <LOQ |
| 11 | Not challenged | NT | NT |
| 12 | S21 | <LOQ | <LOQ |
| 13 | S21 | <LOQ | <LOQ |
| 14 | S21 | <LOQ | <LOQ |

Ten animals previously treated with SAB-139/V6-V8 were back-challenged with a lethal dose of EBOV Makona isolate 77 days after previous challenge. In the EI group, 1/6 animals survived back-challenge. In the DI group, 4/4 animals survived back-challenge. Abbreviations: CSF, cerebrospinal fluid; D, died; DI, delayed intervention (treatment initiated on day 3 postexposure); EI, early intervention (treatment initiated on day 1 postexposure); GE, genome equivalents; LOQ, limit of quantification; NT, not tested. S, survived.